Our aim was to restore NK cell functionality in CLL through a specifically targeted IL15-stimulating activity; IL15 targeting could, in fact, potentiate the activity of NK cells and reduce off-target effects. The gene discussed is IL15; the disease is B-cell chronic lymphocytic leukemia.